Once the registration formalities are completed within the stipulated timeframe, the China Patent Office will decide whether to grant the patent right and then a Letters Patent will be issued by the aforementioned office confirming the registration and announcement.
The subject of patent application CN 201980017745.X ” Antracycline encapsulated with polysaccharide for use in the treatment of tumors” is the use of a new form of drug in the form of an anthracycline encapsulated with polysaccharide for the treatment of certain cancers, in particular when the polysaccharide used is dextran and the anthracycline is epirubicin, and the tumor is ovarian cancer. The subject matter of the invention is in the Company’s core business of increasing the efficacy of existing anti-cancer therapies using polysaccharide nanoparticle technology.